ALLOGENEIC TRANSPLANTATION FROM HLA-HAPLOIDENTICAL DONORS IN KBC ZAGREB

diplomski rad

• Autor: Brian Jacob Melamed
• Mentor: Nadira Duraković (mentor)
• Član povjerenstva: Radovan Vrhovac (predsjednik povjerenstva)
• Član povjerenstva: Jasenka Markeljević (član povjerenstva)
• Član povjerenstva: Nadira Duraković (član povjerenstva)
• Ustanova koja je dodijelila akademski / stručni stupanj: Sveučilište u Zagrebu; Medicinski fakultet; Zagreb
• Datum i država obrane: 2016-09-28, Hrvatska
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti; Interna medicina

Sažetak

Background: The use of haploidentical stem cell transplantation (HSCT) has recently arisen as an effective treatment for refractory hematological malignancies, and several approaches have been shown to offer similar outcomes to HLA-matched allogeneic HSCT with the benefit of a larger and more accessible donor pool, particularly in smaller countries and ethnic minorities. High-dose post-transplant cyclophosphamide (PTCy) is a simple and well-studied approach being newly utilized at UHC Zagreb. Objective: We evaluated several key outcomes of patients receiving haploidentical HSCT at UHC Zagreb in order to determine whether they were acceptable in comparison to other centers performing haploidentical HSCT as well as studies of HLA-matched HSCT. Methods: In a retrospective study, ten patients with various refractory myelogenous and lymphoid malignancies underwent PTCy haploidentical HSCT at UHC Zagreb from 2012-2015. Both myeloablative and RIC conditioning regimens were employed. Data was collected towards the primary endpoints of engraftment, relapse and GVHD rates. Results: Median times to neutrophil and thrombocyte recovery were 12 and 21 days post-transplant, respectively. Relapse rates were 50%, with a mean relapse time of 5.6 months. Rejection rate was 10%. NRM was 20% with a median time of 15.3 months. Acute and chronic GVHD rates were 10% and 30% respectively, with a mean diagnosis time of 11.2 months for chronic GVHD. Conclusion: HLA-haploidentical HSCT at UHC Zagreb using PTCy is associated with acceptable rates of engraftment, relapse, and GVHD.

• Ključne riječi: stem cell transplantation; haploidentical; graft-versus-host; post-transplantation cyclophosphamide
• Jezik: engleski
• URN:NBN: urn:nbn:hr:105:668860
• Studijski program: Naziv: Medicina (na engleskom jeziku); Vrsta studija: sveučilišni; Stupanj studija: integrirani preddiplomski i diplomski; Akademski / stručni naziv: doktor/doktorica medicine (dr. med.)
• Vrsta resursa: Tekst
• Način izrade datoteke: Izvorno digitalna
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2017-08-30 12:16:27